Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or above 18 years~* Male or female gender~* In case of women, unwillingness to remain pregnant during the study period~* Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent~* Community-acquired pneumonia or hospital-acquired pneumonia or ventilator-associated pneumonia or primary bacteremia or acute cholangitis~* Sepsis defined by the Sepsis-3 definitions.~* Patients with laboratory diagnosis of MALS or hypo-inflammation (immune-paralysis) based on two consecutive blood sampling with 24 hours apart. MALS is defined as the presence of ferritin \>4,420 ng/ml and hypo-inflammation as HLA-DR expression on CD14-monocytes (co-expression) less than 30%~Exclusion Criteria:~* Age below 18 years~* Denial for written informed consent~* Acute pyelonephritis or intraabdominal infection other than AC, meningitis or skin infection. It is explicitly stated that in the case of a patient with both AC and any other type of intraabdominal infection, the patient cannot be enrolled.~* Any stage IV malignancy~* Any do not resuscitate decision~* In the case of BSI, patients with blood cultures growing coagulase-negative staphylococci or skin commensals or catheter-related infections cannot be enrolled.~* Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB~* Infection by the human immunodeficiency virus (HIV)~* Any primary immunodeficiency~* Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone or greater the last 15 days~* Any anti-cytokine biological treatment the last one month~* Medical history of systemic lupus erythematosus~* Medical history of multiple sclerosis or any other demyelinating disorder~* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
- IV Placebo (Type: PLACEBO_COMPARATOR): Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
- Recombinant human interferon-gamma (Type: EXPERIMENTAL): Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).